Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Xenon Pharmaceuticals

NASDAQ: XENE ↗$39.26 USD
#Neuroscience#Epilepsy#Psychiatry#Rare Disease

Neurology-focused biopharmaceutical company applying its Extreme Genetics discovery platform to Kv7 and other ion-channel modulators, led by azetukalner for epilepsy and major depressive disorder.

Company Info

Sector:Biopharmaceuticals / Neuroscience
Headquarters:Vancouver, British Columbia, Canada
Founded:1996
Website:xenon-pharma.com/

Clinical Development Pipeline

azetukalner (XEN1101)

Target: Kv7 potassium channel opener
Focal-onset seizures
Preclinical
Phase 1
Phase 2
Phase 3
Approved

azetukalner (XEN1101)

Target: Kv7 potassium channel opener
Major depressive disorder
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Nav1.6 inhibitor program

Target: Nav1.6 sodium channel
SCN8A developmental and epileptic encephalopathy
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Ian Mortimer

President and Chief Executive Officer

Careers & Job Openings

See all open roles

Careers
Vancouver, British Columbia, Canada
Apply Now →